Biogen Idec and Knopp Neurosciences Announce License Agreement for Late-Stage ALS Drug Candidate
08/18/2010-- Biogen Idec expects to initiate Phase 3 program in the first half of 2011 -- Equity investment and potential license payments of $345 million WESTON, MA, and PITTSBURGH, PA, August 18, ......
Knopp Neurosciences Presents Further Encouraging Trends in its Phase 2 Study of KNS-760704 (Dexpramipexole) in ALS
04/16/2010TORONTO, April 16, 2010--In an invited presentation today before the annual meeting of the American Academy of Neurology, Knopp Neurosciences Inc. ("Knopp") described further encouraging trends ......
Knopp Neurosciences Reports Presentation of Encouraging Clinical Trends in a Phase 2 Study of KNS-760704 in ALS
12/09/2009BERLIN, December 9, 2009--Knopp Neurosciences Inc. ("Knopp") announced the presentation today of encouraging clinical results in a Phase 2 safety and tolerability study of KNS-760704 in amyotrophic ......
Knopp Neurosciences Receives FDA Fast Track Designation for KNS-760704 in ALS
09/02/2009PITTSBURGH, PA, USA, SEPTEMBER 2, 2009—Knopp Neurosciences Inc. announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of KNS-760704 in ......
Knopp Neurosciences to Present Phase 2 Results of KNS-760704 in ALS
08/11/2009PITTSBURGH, PA, USA, AUGUST 11, 2009—Knopp Neurosciences Inc. said the results of a Phase 2 safety and tolerability study of KNS-760704 in amyotrophic lateral sclerosis (ALS) will be presented at the ......
Knopp Neurosciences Inc. Sponsors ALS Awareness Day at PNC Park
05/03/2009PITTSBURGH, PA., May 2, 2009--Knopp Neurosciences Inc. acted as presenting sponsor for ALS Awareness Day at PNC Park, which brought together hundreds of patients, caregivers, and community members to ......
European Commission Awards Orphan Designation to KNS-760704 in ALS
03/09/2009PITTSBURGH, Pa., March 10, 2009--Knopp Neurosciences Inc. ("Knopp") today announced that the European Commission ("EC") has designated KNS-760704 as an orphan medicinal product for the treatment of ......
Knopp Neurosciences Completes Series B2 Financing, Raising Total Capitalization to $27 Million
11/19/2008PITTSBURGH, Pa., November 19, 2008--Knopp Neurosciences Inc. ("Knopp") said its current investors exercised $6.6 million in Series B2 warrants, raising the company’s total capitalization to $27 ......
Knopp Neurosciences Initiates Phase 2 Study of KNS-760704 in Amyotrophic Lateral Sclerosis
04/07/2008PITTSBURGH, Pa., April 7, 2008--Knopp Neurosciences Inc. ("Knopp") said it initiated the first Phase 2 study of KNS-760704 in patients with amyotrophic lateral sclerosis (ALS). The study is designed ......
KNS-760704 in ALS Featured in BioCentury
03/31/2008SAN CARLOS, Ca., March 31, 2008--"Knopp Neurosciences Inc. sees therapeutic potential in what was previously considered a throw-away molecule: the R(+) enantiomer of Mirapex pramipexole, which Knopp ......
Knopp Neurosciences Completes First Series B Financing of $10 Million
01/22/2008PITTSBURGH, Pa., January 22, 2008--Knopp Neurosciences Inc. ("Knopp") said it completed a Series B funding round of $10 million, increasing its total capitalization to $20 million. The latest ......
Knopp Neurosciences Presents Results of Phase 1 Ascending Single-Dose Study of KNS-760704
12/03/2007TORONTO, Ontario, December 3, 2007--Knopp Neurosciences Inc. ("Knopp") presented results of its ascending single-dose study of KNS-760704, an orally bioavailable small molecule therapy in development ......
Knopp Neurosciences Receives Orphan Designation
10/15/2007PITTSBURGH, Pa., October 15, 2007--Knopp Neurosciences Inc. ("Knopp") announced that the U.S. Food and Drug Administration’s Office of Orphan Products Development has granted orphan drug designation ......
Cheryl Fossum Graham Joins Knopp Neurosciences as Head of Regulatory and Development Strategy
10/03/2007PITTSBURGH, Pa., October 3, 2007--Knopp Neurosciences Inc. ("Knopp") announced that Cheryl Fossum Graham, M.D., F.C.P., has joined the company as senior vice president of regulatory and development ......
Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704
09/24/2007PITTSBURGH, Pa., September 24, 2007- Knopp Neurosciences Inc. today announced the initiation of a Phase 1 clinical trial of KNS-760704, a small molecule therapy in development for the treatment of ......